Noble Corp. (NYSE:NE): FBR Capital called Noble Corporation a must-own stock over the next several months and said that Friday’s pullback provides a compelling entry point. The firm keeps an Outperform rating on their stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX): Brean Capital noted the impressive results from the Celldex’s Phase 2b trial for their breast cancer drug. The firm believes it could be a blockbuster drug product at its peak, but based on the company’s pipeline and their current market valuation, the shares look undervalued. Shares are Buy rated with a $14 price target.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Omnicare Inc. (NYSE:OCR): Following their Analyst Day, Cowen views Omnicare Inc.’s management’s 2013 outlook as conservative. They are working on strategies that focus on operation efficiency and organic bed growth. Cowen believes that although management reiterated their 2013 guidance, it could prove to be a conservative stance. Shares are Outperform rated.
Global Payments Inc. (NYSE:GPN): Barclays’s checks indicate that Global Payments Inc. is at risk of losing EVO Payments International, one of the largest independent sales organizations. Following two recent acquisitions, the firm thinks that EVO may be looking to bring back-end processing of credit card transactions in-house. The company believes that 15c for earnings per share is at risk and that loss will continue to put pressure on earnings growth. Shares of Global Payments are Equal Weight rated.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Baird is increasingly confident in Alexion’s Solaris prospects both near and long-term. The firm also noted the company’s robust pipeline and current valuation and remains buyers of the shares for a recovery into the $125 range. Shares are Outperform rated.
Don’t Miss: Will “Pay for Delay” Ruling Cost Drug Companies?